Companies / BOC Sciences / Burosumab
BOC Sciences

Burosumab | BOC Sciences

Burosumab is a human monoclonal antibody targeting the phosphaturic hormone fibroblast growth factor 23 (FGF23). Burosumab is currently in a phase III clinical trial for the treatment of patients with X-linked hypophosphatemia.

Reviews


No reviews yet

ABOUT THE COMPANY

BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.